Sugi Predict

Sugi Predict / Compounds / SCHEMBL11566

SCHEMBL11566

SCHEMBL11566

O=C(Cc1cc(F)cc(F)c1)c1ccccc1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.53
▸ HTT P42858 5/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ HPGD P15428 4/20 0.53
▸ MEN1 O00255 3/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ NPC1 O15118 3/20 0.53
▸ ALOX12 P18054 3/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ LMNA P02545 5/20 0.53
▸ KDM4E B2RXH2 4/20 0.53
▸ TSHR P16473 2/20 0.53
▸ CYP19A1 P11511 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ TP53 P04637 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ ESR1 P03372 1/20 0.45
▸ SHBG P04278 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL149865 0.87 HTT (0.61) MAPTHTTKMT2AHPGDMEN1
SCHEMBL17838467 0.81 LMNA (0.58) MAPTHTTKMT2AHPGDMEN1
SCHEMBL22925087 0.81 LMNA (0.77) MAPTHTTKMT2AHPGDMEN1
SCHEMBL29574422 0.81 LMNA (0.77) MAPTHTTKMT2AHPGDMEN1
SCHEMBL29586388 0.80 HPGD (0.56) MAPTHTTKMT2AHPGDMEN1
SCHEMBL8376 0.80 HPGD (0.56) MAPTHTTKMT2AHPGDMEN1
SCHEMBL152533 0.79 ALOX15 (0.51) MAPTHTTKMT2AHPGDSMN1; SMN2
Phloroglucinol SCHEMBL28077693 0.77 LMNA (0.55) MAPTHTTKMT2AHPGDMEN1
SCHEMBL7533339 0.77 CYP19A1 (0.69) MAPTHTTKMT2AHPGDMEN1
SCHEMBL4745782 0.77 MAPT (0.50) MAPTKMT2AHPGDMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 — — US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 — — EP disclosed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 — — EP disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 — — US disclosed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 — — US disclosed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 — — EP disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 — — US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 — — US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 — — US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 — — US disclosed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 MAPT 2596/4885HTT 2231/4885KMT2A 2492/4885
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MAPT 2989/4885HTT 3125/4885KMT2A 3137/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MAPT 2989/4885HTT 3125/4885KMT2A 3137/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MAPT 2989/4885HTT 3125/4885KMT2A 3137/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MAPT 2989/4885HTT 3125/4885KMT2A 3137/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MAPT 2989/4885HTT 3125/4885KMT2A 3137/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A MAPT 3674/4885HTT 3291/4885KMT2A 3863/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MAPT 2989/4885HTT 3125/4885KMT2A 3137/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MAPT 2989/4885HTT 3125/4885KMT2A 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.